Mersana Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc. for $25.00 per share in upfront cash plus contingent value rights worth up to an additional $30.25 per share.
Mersana Therapeutics will be acquired by Day One Biopharmaceuticals for an upfront cash payment of $25.00 per share plus potential contingent value rights of up to $30.25 per share, totaling up to $285 million.
Day One Biopharmaceuticals will acquire Mersana Therapeutics for an upfront cash payment of $25.00 per share, with potential additional payments of up to $30.25 per share through contingent value rights.
Mersana Therapeutics received a notice from Nasdaq for failing to meet the minimum $50 million Market Value of Listed Securities requirement.
Mersana Therapeutics reported Q2 2025 financial results and provided updates on its clinical-stage antibody-drug conjugate programs, Emi-Le and XMT-2056.
Mersana Therapeutics, Inc. will implement a 1-for-25 reverse stock split effective July 25, 2025, to meet Nasdaq's minimum bid price requirement for continued listing.
Mersana Therapeutics, Inc. announced the full repayment of approximately $17.9 million in outstanding debt, leading to the termination of its loan and security agreement with Oxford Finance LLC and its Lenders.
8-K: Mersana Therapeutics Stockholders Approve Reverse Split and Director Elections at Annual Meeting
Mersana Therapeutics, Inc. announced that its stockholders approved all four proposals at the 2025 Annual Meeting, including the election of three Class II directors and a reverse stock split.
Mersana Therapeutics announced additional positive interim Phase 1 clinical data for its B7-H4-directed ADC, Emi-Le, demonstrating encouraging objective response rates and a differentiated safety profile in various advanced cancers, including triple-negative breast cancer and adenoid cystic carcinoma.
Mersana Therapeutics reports encouraging clinical data for Emi-Le in B7-H4 high tumors and unveils its Q1 2025 financial results, highlighting a strategic restructuring plan to extend its cash runway into mid-2026.
Mersana Therapeutics is implementing a strategic restructuring, including a 55% workforce reduction, to extend its cash runway into mid-2026 and focus on advancing Emi-Le in triple-negative breast cancer.
Mersana Therapeutics reports positive initial Phase 1 clinical data for Emi-Le, initiates expansion cohort in TNBC patients, and provides financial results for Q4 and full year 2024.
Mersana Therapeutics received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting the company at risk of delisting.
Mersana Therapeutics, Inc. updated its corporate presentation on its website on February 5, 2025.
Mersana Therapeutics updates its corporate presentation on its website, providing investors with the latest company information.
Mersana Therapeutics reports positive initial Phase 1 clinical trial data for Emiltatug Ledadotin (Emi-Le) and receives an additional FDA Fast Track designation for the treatment of advanced breast cancer.
Mersana Therapeutics has entered into an agreement with EcoR1 Capital affiliates to exchange 8,036,688 common shares for pre-funded warrants.
Mersana Therapeutics reported progress in clinical trials for its ADC candidates and announced its third quarter 2024 financial results, highlighting a strong cash position and reduced operating expenses.
8-K: Mersana Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Mersana Therapeutics announced progress in clinical trials for its lead ADC candidates and reported its second quarter 2024 financial results, highlighting a reduced net loss and sufficient capital to support operations into 2026.
Mersana Therapeutics held its 2024 Annual Meeting of Stockholders, electing two Class I directors and approving executive compensation and the selection of an independent accounting firm.
Mersana Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including the ongoing trials for XMT-1660 and XMT-2056.
Mersana Therapeutics has entered into a sales agreement to potentially sell up to $100 million of its common stock through an at-the-market offering.
Mersana Therapeutics reports progress in clinical trials for XMT-1660 and XMT-2056, along with financial results for Q4 and full year 2023, and expects capital resources to support operations into 2026.